What Happened

mdxhealth published the Oxford GPS-ProMPT study in European Urology Oncology, demonstrating a 92% six-year freedom-from-failure rate in prostate cancer patients with favorable GPS scores. This study lays the groundwork for the GPS-ProtecT randomized controlled trial.

Who Is Affected

Urologists, oncologists, and payers in the prostate cancer treatment space are directly impacted. Patients with localized prostate cancer may benefit from improved risk stratification and treatment decisions.

Market Impact

• Potential for GPS mdx to become a standard in prostate cancer risk assessment.
• Increased adoption in clinical guidelines and payer coverage.
• Opportunities for mdxhealth to expand its market share in precision diagnostics.

What to Watch

Monitor the progress of the GPS-ProtecT trial and its impact on clinical guidelines. Track payer adoption and physician uptake of GPS mdx in prostate cancer management.